About the Company
Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company's first rare disease therapy, FINTEPLA® (fenfluramine) oral solution has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy. The company has two additional late-stage development programs underway: one for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome, another rare epilepsy, and one for MT1621, an investigational therapy for the treatment of a rare genetic disorder called TK2 deficiency. Zogenix is also collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ZGNX News
Zogenix Inc
A special interest's lobbying activity may go up or down over time, depending on how much attention the federal government is giving their issues. Particularly active clients often retain multiple ...
After epilepsy setback, Zogenix buys Modis and rare disease drug for $400m
Zogenix will also pay a 5% royalty on any future net sales of MT1621. Zogenix’s other drug candidate for a rare kind of childhood epilepsy is facing a delay after the FDA refused in April to ...
Kim P. Kamdar's Net Worth
Who is Kim P. Kamdar? Kim P. Kamdar has an estimated net worth of $2.25 Million. This is based on reported shares across multiple companies, which include MARINUS PHARMACEUTICALS INC, GLAUKOS Corp ...
Welcome to Inc.'s Directory of B2B Excellence
They all made it through Inc.'s proprietary vetting process, based in part on testimonials from other clients. As any entrepreneur knows, the right partnership can make all the difference.
Elite Pharmaceuticals, Inc. (ELTP)
Elite Pharmaceuticals, Inc. (PNK:ELTP) Q3 2024 Earnings Call Transcript February 15, 2024 Elite Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the ...
Etsy Inc.
1 Day ETSY -0.46% DJIA 0.67% S&P 500 0.87% Retail/Wholesale 0.37% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the ...
About Inc.com | Everything You Need to Know to Grow and Start Your Business
Inc. is the voice of the American entrepreneur. We inspire, inform, and document the most fascinating people in business: the risk-takers, the innovators, and the ultra-driven go-getters that ...
Fidelity Management & Research Co. 3Q 13F: Largest Eliminations
PDL BIOPHARMA INC COM PDLI (6,373,539) GERON CORP COM GERN (5,934,900) RUBICON MINERALS CORP COM RBY (5,087,102) ZOGENIX INC COM ZGNX (5,078,997) TUESDAY MORNING CORP COM TUES (4,057,530 ...
Tesla, Inc. (TSLA)
Tesla will report Q1 earnings after the bell on Tuesday, giving a much-needed update on the EV maker’s current and future prospects as investor sentiment slides. Tesla (TSLA) is asking ...
‘Food, Inc. 2’ Review: A Second Course
Share full article “Food, Inc. 2,” directed by Robert Kenner and Melissa Robledo, begins by describing how the last few years have shown the risks of letting a handful of mega-suppliers ...
Loading the latest forecasts...